Mucosal immunity is our vision,

Infectious diseases, oncology and chronic inflammations our investigation fields,

Innovation our focus !

New product: GM1 IgM

B Cell Design's offer is on the move !

Autoimmunity line products extends: GM1 IgM

Our products line of autoimmunity positive controls progress and counts IgM now. Try out our new Monosialoganglioside GM1 IgM.

Read more

New product : Rubella IgM

B Cell Design's offer is on the move!

No more sourcing issues for Rubella IgM 

The antibodies solution: what if your positive control was industrially produced ?
Replace the human disease state plasma by more reproducible and reliable products !

Read more

New products: HSV1 IgM and HSV2 IgM

B Cell Design’s offer is on the move !

TORCH panel extents: HSV1 IgM and HSV2 IgM

The antibodies solution: what if your positive control was industrially produced ?
Replace the human disease state plasma by more reproducible and reliable products !

Read more

From therapeutic researches to IVD solutions

Our solutions

Mucosal immunity

b-Cell-Design

B Cell Design develops a new mucosal immunotherapy approach for generating a large number of drug and vaccine candidates in infectious field and oncology.
The innovation is based on a genetically modified mouse model (HAMIGA) producing chimeric human IgA. IgA is a class of antibodies particularly involved in the immunity of mucosal area (lung, gut, genital tract, ...) and associated glands (breast, prostate). Because of this characteristic, IgA is a well-adapted tool to develop innovative treatment for both infectious diseases and mucosal cancer.

 

 

Learn more

The antibodies solution

B Cell Design offers to diagnostics companies a reliable, reproducible and secured source of chimeric human antibodies for several purposes:

  • Calibrators, positive controls and quality controls for in vitro diagnostics kits to replace human disease state plasma.
  • Immunocapture antibodies to replace mice antibodies which triggers false positives or negatives due to HAMA antibodies.
  • Research reagents (development or renewal of diagnostic kits, improvment of the products portfolio…)

 

 

Learn more

Our expertise

B Cell Design focuses on mucosal immunotherapy which led B Cell Design to develop two groundbreaking drug candidates:

  • A vaccine candidate in infectious diseases field: a worldwide patented HIV vaccine (A new non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection – Europe Patent 14305174.6) to prevent or even cure HIV infections. Preliminary studies showed that this approach elicits an efficient local immune response, neutralizing HIV infection of human cells.
  • A drug candidate in oncology field (colorectal cancer) for immunotherapy, radioimmunotherapy applications or medical imaging.


ArkAb, internal division of B Cell Design, is dedicated to the in vitro diagnostics market. Through its patented technology (HAMIGA, GAMMAPRIM, INEPS), B Cell Design develops and manufactures human chimeric antibodies to replace human disease state plasma currently used as calibrators, positive controls and quality controls.